Cargando…

Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis

Meta-analysis was used to evaluate the efficacy of Fufang Biejia Ruangan Tablets in the treatment of chronic hepatitis B (CHB) liver fibrosis. METHODS: Databases, including PubMed, China Knowledge Network (CNKI), China Biomedical Database (CBM), Wan Fang, VIP database, Embase, and Cochrane Library w...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Xiangbo, Pan, Zhengqi, Zhao, Jiawei, Feng, Quansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678545/
https://www.ncbi.nlm.nih.gov/pubmed/36401442
http://dx.doi.org/10.1097/MD.0000000000031664
_version_ 1784834010037354496
author Meng, Xiangbo
Pan, Zhengqi
Zhao, Jiawei
Feng, Quansheng
author_facet Meng, Xiangbo
Pan, Zhengqi
Zhao, Jiawei
Feng, Quansheng
author_sort Meng, Xiangbo
collection PubMed
description Meta-analysis was used to evaluate the efficacy of Fufang Biejia Ruangan Tablets in the treatment of chronic hepatitis B (CHB) liver fibrosis. METHODS: Databases, including PubMed, China Knowledge Network (CNKI), China Biomedical Database (CBM), Wan Fang, VIP database, Embase, and Cochrane Library were searched. The time was searched up to May 2022. The participant intervention comparator outcomes of this study were as follows: P, patients with CHB liver fibrosis; I, Fufang Biejia Ruangan Tablets; C, pharmacological placebo; O, the efficacy rate, alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), albumin (ALB), procollagen III protein (PIIIP), hyaluronic acid (HA), laminin (LN), collagen C type IV (IV-C), portal vein diameter, spleen thickness and HBV‐DNA negative conversion rate. The Cochrane Risk of Bias tool, Begg’s test and Egger’s test were used to evaluate the methodological quality of eligible studies. A randomized controlled trial of Fufang Biejia Ruangan Tablets was used to treat CHB liver fibrosis. Three reviewers independently selected trials, extracted data, cross-checked, and performed methodological quality assessments. Data analysis was completed by Review Manager 5.3. RESULTS: Twenty-six studies with 2717 patients were included in the meta‐analysis. The meta-analysis showed that Fufang Biejia Ruangan Tablets was effective by increasing the efficacy. Fufang Biejia Ruangan Tablets was more efficient in improving ALT, AST, TBIL, ALB, PIIIP, HA, LN, IV-C, portal vein diameter, spleen thickness, and HBV‐DNA negative conversion rate with no serious adverse reactions. CONCLUSION: It was shown that Fufang Biejia Ruangan Tablets can effectively improve liver function and relieve liver fibrosis, but future research should focus on rigorously designed, multicenter, and large randomized controlled trials.
format Online
Article
Text
id pubmed-9678545
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96785452022-11-22 Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis Meng, Xiangbo Pan, Zhengqi Zhao, Jiawei Feng, Quansheng Medicine (Baltimore) 4800 Meta-analysis was used to evaluate the efficacy of Fufang Biejia Ruangan Tablets in the treatment of chronic hepatitis B (CHB) liver fibrosis. METHODS: Databases, including PubMed, China Knowledge Network (CNKI), China Biomedical Database (CBM), Wan Fang, VIP database, Embase, and Cochrane Library were searched. The time was searched up to May 2022. The participant intervention comparator outcomes of this study were as follows: P, patients with CHB liver fibrosis; I, Fufang Biejia Ruangan Tablets; C, pharmacological placebo; O, the efficacy rate, alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), albumin (ALB), procollagen III protein (PIIIP), hyaluronic acid (HA), laminin (LN), collagen C type IV (IV-C), portal vein diameter, spleen thickness and HBV‐DNA negative conversion rate. The Cochrane Risk of Bias tool, Begg’s test and Egger’s test were used to evaluate the methodological quality of eligible studies. A randomized controlled trial of Fufang Biejia Ruangan Tablets was used to treat CHB liver fibrosis. Three reviewers independently selected trials, extracted data, cross-checked, and performed methodological quality assessments. Data analysis was completed by Review Manager 5.3. RESULTS: Twenty-six studies with 2717 patients were included in the meta‐analysis. The meta-analysis showed that Fufang Biejia Ruangan Tablets was effective by increasing the efficacy. Fufang Biejia Ruangan Tablets was more efficient in improving ALT, AST, TBIL, ALB, PIIIP, HA, LN, IV-C, portal vein diameter, spleen thickness, and HBV‐DNA negative conversion rate with no serious adverse reactions. CONCLUSION: It was shown that Fufang Biejia Ruangan Tablets can effectively improve liver function and relieve liver fibrosis, but future research should focus on rigorously designed, multicenter, and large randomized controlled trials. Lippincott Williams & Wilkins 2022-11-18 /pmc/articles/PMC9678545/ /pubmed/36401442 http://dx.doi.org/10.1097/MD.0000000000031664 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 4800
Meng, Xiangbo
Pan, Zhengqi
Zhao, Jiawei
Feng, Quansheng
Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis
title Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis
title_full Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis
title_fullStr Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis
title_full_unstemmed Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis
title_short Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis
title_sort efficacy and safety of fufang biejia ruangan tablets as an adjuvant treatment for chronic hepatitis b liver fibrosis: a systematic review and meta-analysis
topic 4800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678545/
https://www.ncbi.nlm.nih.gov/pubmed/36401442
http://dx.doi.org/10.1097/MD.0000000000031664
work_keys_str_mv AT mengxiangbo efficacyandsafetyoffufangbiejiaruangantabletsasanadjuvanttreatmentforchronichepatitisbliverfibrosisasystematicreviewandmetaanalysis
AT panzhengqi efficacyandsafetyoffufangbiejiaruangantabletsasanadjuvanttreatmentforchronichepatitisbliverfibrosisasystematicreviewandmetaanalysis
AT zhaojiawei efficacyandsafetyoffufangbiejiaruangantabletsasanadjuvanttreatmentforchronichepatitisbliverfibrosisasystematicreviewandmetaanalysis
AT fengquansheng efficacyandsafetyoffufangbiejiaruangantabletsasanadjuvanttreatmentforchronichepatitisbliverfibrosisasystematicreviewandmetaanalysis